top of page
Browse by category
Search
First patient enrolled in a Phase 2 Study in T2DM patients with Olatec's NLRP3 inhibitor dapansutrile
The first patient with T2DM and diabetes-related complications has been enrolled in the clinical trial, DAPAN-DIA, in Basel, Switzerland,...
EMA issues recommendations for GLP-1ra to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation
European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended new measures to minimise the risk of...
Amylyx acquires avexitide GLP-1ra post-bariatric hypoglycaemia from Eiger BioPharmaceuticals
Amylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, an investigational, first-in-class glucagon-like peptide-1...
Biophytis obtains IND approval to start its phase 2 OBA study in obesity
Biophytis has received Investigational New Drug (IND) approval from the FDA for its phase 2 OBA clinical study in obesity with BIO101...
Researchers discover neurons in the brain that controls food intake without causing nausea in an animal model
By teasing apart the therapeutic benefits from the adverse effects of glucagon-like peptide-1 receptor (GLP1R) agonists, researchers from...
Journal Watch 10/7/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Patients receiving tirzepatide were significantly more likely to achieve clinically meaningful weight loss compared with those treated receiving semaglutide
Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight...
Novel regulatory mechanism governing reactive oxygen species production associated with metabolic and immune pathway interactions in obesity
A novel regulatory mechanism governing reactive oxygen species (ROS) production in macrophages in response to energy overload, in which...
GLP-1RA may reduce the risk of specific obesity-associated cancers
Glucagon-like peptide 1 receptor agonists (GLP-1RA) may reduce the risk of specific obesity-associated cancers, according to a study by...
Most Americans do not use GLP-1s long enough to see meaningful weight-loss
The largest study to date has reported that despite the explosion in demand for GLP-1s, 58% of patients discontinue use before reaching a...
Browse by tag
bottom of page